Skip to main content

Bavarian Nordic

Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines for infectious diseases and travel health. The company produces non-replicating smallpox and mpox vaccines marketed under brand names like Jynneos and Imvanex, alongside commercial travel vaccines for rabies and tick-borne encephalitis. Its clinical pipeline targets respiratory syncytial virus, chikungunya, and specialized immunotherapies utilizing its proprietary MVA-BN viral vector vaccine platform. Principal revenue is derived from bulk government supply contracts for national strategic smallpox and mpox stockpiles, commercial travel vaccine sales to healthcare channels, and biodefense research development funding. Bavarian Nordic holds a global market position as a primary international supplier of non-replicating smallpox and mpox vaccines. Headquartered in Hellerup, Denmark, the company's common stock is publicly listed and traded on Nasdaq Copenhagen under the ticker BNO.

18 of the funds FundTelligence covers report a position in Bavarian Nordic.

Legal name
Bavarian Nordic AS
Sector
Health Care
Country
Denmark
Funds holding it
18

Funds holding Bavarian Nordic

Showing the 8 largest of 18 funds holding it.

Loading...